(Hims & Hers, NYSE: HIMS), the leading health and wellness platform, today shared more data on the challenges Americans are facing when trying to access branded GLP-1 medication and introduced a GLP-1 Supply Tracker, where individuals can be a part of advocating for better access to the medications they need
Future Regulatory Outlook: If ongoing Phase 23 trials in men demonstrate clear safety and efficacy, we could see an FDA submission for a male indication (for ED or another male sexual disorder) in a couple of years
This is a major differentiator from full HGH, which can worsen insulin resistance at therapeutic doses
These publications help frame GHK-Cu as a biologically active copper-binding peptide rather than as an established treatment for every claimed use
Vitamin E and C supplementation and risk of cancer in men: posttrial follow-up in the Physicians' Health Study II randomized trial
In one example of a physiological response to osmotic pressure, in early mammary gland milk production osmoregulatory pathways are exploited using asymmetric kinetics to increase the carnitine concentration in milk for suckling neonates who have reduced carnitine stores, even though this results in decreased maternal liver stores [20]